Dong Yujie, Zhang Butian, Yang Qi, Zhu Jiajing, Sun Xiaojie
Department of Emergency, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Clin Rheumatol. 2021 Jan;40(1):263-277. doi: 10.1007/s10067-020-05185-2. Epub 2020 Jun 12.
We conducted this updated meta-analysis to evaluate the effects of PRP in patients with knee or hip OA.
PubMed, Embase, and Web of Science were searched to identify randomized controlled trials (RCTs) that compared the efficacy of PRP with other intra-articular injections. The outcomes of interest included Western Ontario and McMaster (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Visual Analog Scale (VAS), Harris Hip Score (HHS), and International Knee Documentation Committee (IKDC).
Twenty-four RCTs with 21 at knee OA and three at hip OA were included in this meta-analysis. The PRP injections significantly improved the WOMAC score, VAS score, IKDC score, and HHS score as compared with comparators. The WOMAC pain, stiffness, and physical function scores were also significantly better in the PRP group than in the control group. Most of the evaluated parameters that favored PRP were observed in knee OA but not in hip OA, at short-term (at 1, 2, 3, 6, 12 months) but not long-term follow-up (at 18 months), in RCTs with low risk of bias.
Intra-articular PRP injection provided better effects than other injections for OA patients, especially in knee OA patients, in terms of pain reduction and function improvement at short-term follow-up. Key Points • This updated meta-analysis, based on great sample size and high-quality studies, evaluates the effects of PRP in patients with knee or hip OA. • Intra-articular PRP injection provided better effects than other injections for OA patients. • Most of the evaluated parameters that favored PRP were observed in knee OA at short term (at 1, 2, 3, 6, 12 months).
我们进行了这项更新的荟萃分析，以评估富血小板血浆（PRP）对膝或髋骨关节炎（OA）患者的疗效。
检索PubMed、Embase和Web of Science，以确定比较PRP与其他关节内注射疗效的随机对照试验（RCT）。感兴趣的结局包括西安大略和麦克马斯特大学骨关节炎指数（WOMAC）、膝关节损伤和骨关节炎结局评分（KOOS）、视觉模拟评分（VAS）、Harris髋关节评分（HHS）以及国际膝关节文献委员会（IKDC）评分。
本荟萃分析纳入了24项RCT，其中21项针对膝OA，3项针对髋OA。与对照相比，PRP注射显著改善了WOMAC评分、VAS评分、IKDC评分和HHS评分。PRP组的WOMAC疼痛、僵硬和身体功能评分也显著优于对照组。在低偏倚风险的RCT中，大多数支持PRP的评估参数在膝OA的短期（1、2、3、6、12个月）观察到，但在髋OA未观察到；在长期随访（18个月）未观察到。
关节内注射PRP对OA患者，尤其是膝OA患者，在短期随访中减轻疼痛和改善功能方面比其他注射效果更好。要点 • 这项基于大样本量和高质量研究的更新荟萃分析评估了PRP对膝或髋OA患者的疗效。 • 关节内注射PRP对OA患者比其他注射效果更好。 • 大多数支持PRP的评估参数在膝OA的短期（1、2、3、6、12个月）观察到。
